Hyperion Capital Advisors LP Buys New Position in Globus Medical, Inc. $GMED

Hyperion Capital Advisors LP bought a new stake in shares of Globus Medical, Inc. (NYSE:GMED) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 146,857 shares of the medical device company’s stock, valued at approximately $12,822,000. Globus Medical accounts for 6.3% of Hyperion Capital Advisors LP’s holdings, making the stock its 6th biggest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Wealthspire Advisors LLC boosted its holdings in Globus Medical by 11.4% in the fourth quarter. Wealthspire Advisors LLC now owns 2,645 shares of the medical device company’s stock valued at $231,000 after purchasing an additional 271 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Globus Medical by 203.0% in the fourth quarter. Quadrant Capital Group LLC now owns 7,817 shares of the medical device company’s stock valued at $683,000 after purchasing an additional 5,237 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in Globus Medical by 28.5% in the fourth quarter. Advisors Asset Management Inc. now owns 1,725 shares of the medical device company’s stock valued at $151,000 after purchasing an additional 383 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in Globus Medical by 404.0% in the fourth quarter. Soleus Capital Management L.P. now owns 887,000 shares of the medical device company’s stock valued at $77,444,000 after purchasing an additional 711,000 shares during the last quarter. Finally, Hollencrest Capital Management purchased a new position in Globus Medical in the fourth quarter valued at about $51,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Down 0.1%

Shares of Globus Medical stock opened at $80.44 on Friday. The firm has a market cap of $10.92 billion, a P/E ratio of 18.71, a P/E/G ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The business has a 50-day moving average price of $85.77 and a 200 day moving average price of $88.10.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same quarter last year, the company posted $0.68 earnings per share. Globus Medical’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities research analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 18.38% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Piper Sandler reissued an “overweight” rating on shares of Globus Medical in a report on Tuesday. Royal Bank Of Canada boosted their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.